Table 5 Association between MMP2/9 overexpression and clinicopathological features in breast cancer patients
Clinicopathological feature | MMP2 | MMP9 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
No. of patients | I2 (%) | Model | Pooled OR (95%CI) | P | No. of patients | I2 (%) | Model | Pooled OR (95%CI) | P | |
Tumor size (> 2 cm vs ≤2 cm) | 1254 | 48.4 | R | 1.17 (0.78–1.75) | 0.448 | 3005 | 0 | F | 1.32 (1.13–1.54) | < 0.001 |
Tumor size (> 5 cm vs ≤5 cm) | 1286 | 15.9 | F | 1.12 (0.76–1.64) | 0.568 | 924 | 0 | F | 2.02 (1.28–3.17) | 0.002 |
Lymph node status (+ vs -) | 1606 | 40.3 | R | 1.22 (0.88–1.70) | 0.225 | 1945 | 77.1 | R | 2.90 (1.86–4.53) | < 0.001 |
Distant metastasis (+ vs -) | 219 | 22.0 | F | 2.69 (1.35–5.39) | 0.005 | – | – | – | – | – |
ER (+ vs -) | 1784 | 47.1 | R | 0.82 (0.57–1.18) | 0.290 | 1975 | 58.2 | R | 1.00 (0.71–1.39) | 0.990 |
PR (+ vs -) | 1660 | 5.7 | F | 1.07 (0.85–1.35) | 0.545 | 1876 | 55.2 | R | 1.00 (0.73–1.38) | 0.991 |
HER2 (+ vs -) | 361 | 64.8 | R | 1.28 (0.49–3.37) | 0.612 | 1007 | 0 | F | 1.41 (1.05–1.90) | 0.021 |
TNM stage (III-IV vs I-II) | 666 | 28.0 | F | 2.09 (1.36–3.21) | 0.001 | 2419 | 70.7 | R | 2.00 (1.26–3.19) | 0.004 |
Grade (2–3 vs 1) | 1437 | 0 | F | 2.11 (1.55–2.88) | < 0.001 | 2051 | 61.9 | R | 1.55 (0.91–2.62) | 0.107 |
Grade (3 vs 1–2) | 1089 | 0 | F | 1.53 (1.14–2.06) | 0.005 | 2609 | 48.4 | R | 1.77 (1.32–2.36) | < 0.001 |